SEGMENT INFORMATION (Tables)

6 Months Ended

Apr. 30, 2022

		2022			2021			2022			2021
	For the Three Months Ended April 30,						For the Six Months Ended April 30,
	2022			2021			2022			2021
Net Loss:
CAR-T Therapeutics	$	(1,399	)	$	(1,446	)	$	(3,010	)	$	(2,406	)
Cancer Vaccines		(1,423	)		(662	)		(2,780	)		(1,569	)
Anti-Viral Therapeutics		(757	)		(310	)		(1,661	)		(791	)
Other		(9	)		(19	)		(16	)		97
Total	$	(3,588	)	$	(2,437	)	$	(7,467	)	$	(4,669	)
Net loss	$	(3,588	)	$	(2,437	)	$	(7,467	)	$	(4,669	)
Total operating costs and expenses	$	3,589		$	2,437		$	7,469		$	5,183
Less non-cash share-based compensation		(1,681	)		(1,051	)		(4,036	)		(2,037	)
Operating costs and expenses excluding non-cash share-based compensation	$	1,908		$	1,386		$	3,433		$	3,146
Operating costs and expenses excluding non-cash share based compensation:
CAR-T Therapeutics	$	759		$	935		$	1,427		$	1,492
Cancer Vaccines		740			299			1,220			837
Anti-Viral Therapeutics		402			138			774			409
Other		7			14			12			408
Total	$	1,908		$	1,386		$	3,433		$	3,146
Operating costs and expenses excluding non-cash share based compensation expense	$	1,908		$	1,386		$	3,433		$	3,146